Name | Number of supported studies | Average coverage | |
---|---|---|---|
conventional dendritic cell | 19 studies | 30% ± 11% | |
ciliated cell | 9 studies | 23% ± 7% | |
dendritic cell | 8 studies | 26% ± 10% | |
epithelial cell | 7 studies | 27% ± 7% | |
retinal cone cell | 5 studies | 42% ± 24% | |
type B pancreatic cell | 4 studies | 49% ± 16% | |
glutamatergic neuron | 4 studies | 33% ± 15% | |
macrophage | 4 studies | 20% ± 2% | |
neuroendocrine cell | 4 studies | 53% ± 17% | |
luminal hormone-sensing cell of mammary gland | 4 studies | 28% ± 5% | |
Langerhans cell | 3 studies | 47% ± 23% | |
pancreatic D cell | 3 studies | 58% ± 24% | |
mononuclear phagocyte | 3 studies | 22% ± 5% | |
retinal ganglion cell | 3 studies | 32% ± 5% | |
extravillous trophoblast | 3 studies | 27% ± 15% | |
placental villous trophoblast | 3 studies | 75% ± 14% | |
retinal rod cell | 3 studies | 36% ± 12% | |
enterocyte | 3 studies | 42% ± 8% | |
monocyte-derived dendritic cell | 3 studies | 21% ± 5% | |
GABAergic neuron | 3 studies | 34% ± 8% | |
enteroendocrine cell | 3 studies | 29% ± 14% | |
goblet cell | 3 studies | 26% ± 11% | |
abnormal cell | 3 studies | 18% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 97% | 338.91 | 237 / 245 | 95% | 23.35 | 479 / 502 |
pancreas | 97% | 181.85 | 317 / 328 | 76% | 9.99 | 135 / 178 |
breast | 70% | 314.76 | 320 / 459 | 94% | 58.26 | 1053 / 1118 |
brain | 94% | 2207.01 | 2483 / 2642 | 45% | 9.76 | 314 / 705 |
stomach | 81% | 1203.08 | 289 / 359 | 48% | 5.85 | 136 / 286 |
kidney | 80% | 93.93 | 71 / 89 | 48% | 4.52 | 432 / 901 |
intestine | 61% | 1450.28 | 593 / 966 | 57% | 7.79 | 303 / 527 |
lung | 57% | 136.22 | 328 / 578 | 54% | 9.54 | 621 / 1155 |
skin | 70% | 177.15 | 1274 / 1809 | 27% | 3.22 | 129 / 472 |
liver | 48% | 62.92 | 108 / 226 | 34% | 6.27 | 138 / 406 |
adrenal gland | 44% | 65.02 | 114 / 258 | 37% | 10.15 | 84 / 230 |
esophagus | 33% | 53.08 | 475 / 1445 | 37% | 4.46 | 67 / 183 |
uterus | 23% | 51.11 | 39 / 170 | 40% | 5.32 | 184 / 459 |
bladder | 14% | 12.14 | 3 / 21 | 47% | 7.70 | 239 / 504 |
thymus | 36% | 38.55 | 232 / 653 | 25% | 1.97 | 154 / 605 |
ovary | 4% | 5.72 | 8 / 180 | 37% | 2.91 | 157 / 430 |
adipose | 28% | 30.72 | 343 / 1204 | 0% | 0 | 0 / 0 |
spleen | 25% | 26.18 | 61 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 24% | 1.33 | 11 / 45 |
blood vessel | 22% | 34.45 | 291 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 3% | 0.17 | 1 / 29 |
heart | 3% | 5.01 | 24 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 1% | 0.15 | 1 / 80 |
muscle | 1% | 0.76 | 7 / 803 | 0% | 0 | 0 / 0 |
peripheral blood | 1% | 1.44 | 7 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0032212 | Biological process | positive regulation of telomere maintenance via telomerase |
GO_1904355 | Biological process | positive regulation of telomere capping |
GO_0051973 | Biological process | positive regulation of telomerase activity |
GO_2000480 | Biological process | negative regulation of cAMP-dependent protein kinase activity |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0004862 | Molecular function | cAMP-dependent protein kinase inhibitor activity |
Gene name | PKIB |
Protein name | cAMP-dependent protein kinase inhibitor cAMP-dependent protein kinase inhibitor beta cAMP-dependent protein kinase inhibitor beta (PKI-beta) |
Synonyms | PRKACN2 |
Description | FUNCTION: Extremely potent competitive inhibitor of cAMP-dependent protein kinase activity, this protein interacts with the catalytic subunit of the enzyme after the cAMP-induced dissociation of its regulatory chains. . FUNCTION: Extremely potent competitive inhibitor of cAMP-dependent protein kinase activity, this protein interacts with the catalytic subunit of the enzyme after the cAMP-induced dissociation of its regulatory chains. . FUNCTION: Extremely potent competitive inhibitor of cAMP-dependent protein kinase activity, this protein interacts with the catalytic subunit of the enzyme after the cAMP-induced dissociation of its regulatory chains. . |
Accessions | Q5T0Z6 ENST00000696716.1 ENST00000368446.1 ENST00000392490.5 [Q9C010-1] Q9C010 ENST00000368452.7 [Q9C010-1] ENST00000392491.6 [Q9C010-1] ENST00000258014.3 [Q9C010-2] A0A8Q3SIW0 ENST00000615438.4 [Q9C010-2] ENST00000354275.2 [Q9C010-1] ENST00000368448.5 [Q9C010-1] |